Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 4/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22519796 | 0.82 | MCL1 (0.41) | MCL1DPP4MEN1KMT2AALDH1A1 | |
| SCHEMBL769518 | 0.81 | MCL1 (0.39) | MCL1 | |
| SCHEMBL9713568 | 0.81 | MCL1 (0.41) | MCL1DPP4MEN1KMT2AALDH1A1 | |
| SCHEMBL330556 | 0.79 | MCL1 (0.38) | MCL1 | |
| SCHEMBL28031057 | 0.79 | MCL1 (0.38) | MCL1 | |
| SCHEMBL22833607 | 0.77 | MCL1 (0.37) | MCL1 | |
| SCHEMBL133731 | 0.77 | — | — | |
| SCHEMBL4075198 | 0.76 | MCL1 (0.35) | MCL1 | |
| SCHEMBL1015369 | 0.76 | MCL1 (0.35) | MCL1 | |
| SCHEMBL14234360 | 0.76 | CES2 (0.39) | MCL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115667253-B | Compounds useful for inhibiting RET kinase | 伊莱利利公司 | 2025-06-17 | — | — | CN | disclosed |
| CN-116438179-A | Pyrazole derivatives as RET kinase inhibitors | 伊莱利利公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2022098970-A9 | PYRAZOLE DERIVATIVES AS RET KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-04-27 | — | — | WO | disclosed |
| CN-115667253-A | Compounds useful for inhibition of RET kinase | 伊莱利利公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2022098970-A1 | PYRAZOLE DERIVATIVES ASR ET KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2022-05-12 | — | — | WO | disclosed |
| US-9562052-B2 | Bicyclicpyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-02-07 | — | — | US | disclosed |
| EP-2888245-B1 | NEW BICYCLICPYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-09-21 | — | — | EP | disclosed |
| US-20150368256-A1 | NEW BICYCLICPYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-8076356-B2 | Triazolopyridinylsulfanyl derivatives as P38 map kinase inhibitors | PFIZER INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20090239899-A1 | Triazolopyridinylsulfanyl Derivatives As P38 Map Kinase Inhibitors | PFIZER INC. | 2009-09-24 | — | — | US | disclosed |
| EP-1778686-B9 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | PFIZER LTD (GB) | 2009-07-08 | — | — | EP | disclosed |
| US-7511057-B2 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER INC. (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1778686-B1 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | PFIZER LTD (GB) | 2008-10-29 | — | — | EP | disclosed |
| EP-1778686-A2 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | Pfizer Limited (GB) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006018718-A2 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | PFIZER LIMITED (GB) | 2006-02-23 | — | — | WO | disclosed |
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER INC. | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | MAPK1, MAPKAPK5, MAPKAPK3 | MCL1 4136/4885DPP4 3678/4885MEN1 4865/4885 |
| US-20150368256-A1 | NEW BICYCLICPYRIDINE DERIVATIVES | CACNA1E, CHRM1, CHRM2 | MCL1 422/4885DPP4 2966/4885MEN1 906/4885 |
| US-20090239899-A1 | Triazolopyridinylsulfanyl Derivatives As P38 Map Kinase Inhibitors | MAPK1, MAPKAPK5, MAPKAPK3 | MCL1 4162/4885DPP4 3509/4885MEN1 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.